Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Lululemon, Airbnb Fall Premarket; Zynga, Tilray Rise

Published 10/01/2022, 13:30
Updated 10/01/2022, 13:30
© Reuters.

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Monday, January 10th. Please refresh for updates.

  • Lululemon Athletica (NASDAQ:LULU) stock fell 6% after the athletic apparel retailer warned that its holiday quarter results will be hit as the Omicron variant of the coronavirus forced it to cut down on staffing and store hours.

  • Zynga (NASDAQ:ZNGA) stock soared over 50% after Take-Two Interactive  (NASDAQ:TTWO), down 10%, announced plans to buy the video games developer for $12,7 billion in cash.

  • Airbnb (NASDAQ:ABNB) stock fell 3.2% after Piper Sandler downgraded its stance on the online housing marketplace to “neutral” from “overweight”, with the stock up over 12% over the last year.

  • Moderna (NASDAQ:MRNA) stock rose 0.9% after the drugmaker announced it had lifted its revenue forecast for 2022, seeing advanced purchase agreements of $18.5 billion, up from $17 billion announced in November.

  • Nike (NYSE:NKE) stock fell 2.6% after HSBC downgraded its stance on the sports footwear manufacturer to “hold” from “buy”, citing lingering production issues and slowing demand in China.

  • Tilray (NASDAQ:TLRY) stock rose 8.1% after the cannabis producer reported an unexpected quarterly profit, with revenue up by 20% from a year earlier.

  • ViacomCBS (NASDAQ:VIAC) stock rose 3.5% after Deutsche Bank upgraded its stance on the media giant to “buy” from “hold”, citing positive prospects for its streaming business and the potential for further industry consolidation.

  • Apria (NASDAQ:APR) stock rose over 24% after the home healthcare provider agreed to be bought by Owens & Minor (NYSE:OMI), down 4.6%, for around $1.5 billion in cash.

  • Beam Therapeutics (NASDAQ:BEAM) stock rose 5.5% after the gene-editing specialist agreed a deal with Pfizer (NYSE:PFE), which could be worth around $1.35 billion

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.